A5017669867- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Sphingolipid Metabolism and Signaling
- Thyroid Cancer Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Pancreatic and Hepatic Oncology Research
- Hedgehog Signaling Pathway Studies
- Melanoma and MAPK Pathways
- Radiomics and Machine Learning in Medical Imaging
- Molecular Biology Techniques and Applications
- Cytokine Signaling Pathways and Interactions
- Cancer Research and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer-related Molecular Pathways
- HER2/EGFR in Cancer Research
- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- BRCA gene mutations in cancer
- Peptidase Inhibition and Analysis
Federico II University Hospital
2016-2025
University of Naples Federico II
2016-2025
University of Messina
2023
Queen Alexandra Hospital
2021
University of Maryland, Baltimore
2019
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
2019
Sapienza University of Rome
2018
Retina Institute
2018
Diamant (Germany)
2018
The University of Queensland
2018
The CBX7 gene encodes a polycomb group protein that is known to be downregulated in many types of human cancers, although the role this carcinogenesis remains unclear. To shed light on issue, we generated mice null for Cbx7. Mouse embryonic fibroblasts derived from these had higher growth rate and reduced susceptibility senescence compared with their WT counterparts. This was associated upregulated expression multiple cell cycle components, including cyclin E, which play key lung humans....
When tumour tissue is unavailable, cell-free DNA (cfDNA)can serve as a surrogate for genetic analyses. Because mutated alleles in cfDNA are usually below 1%, next-generation sequencing (NGS)must be narrowed to target only clinically relevant genes. In this proof-of-concept study, we developed panel use ultra-deep identify such mutations cfDNA.Our ('SiRe') covers 568 six genes (EGFR, KRAS, NRAS, BRAF, cKIT and PDGFRα)involved non-small-cell lung cancer (NSCLC), gastrointestinal stromal...
Resistance to tyrosine kinase inhibitors (TKI) of EGF receptor (EGFR) is often related activation other signaling pathways and evolution through a mesenchymal phenotype.Because the Hedgehog (Hh) pathway has emerged as an important mediator epithelial-to-mesenchymal transition (EMT), we studied Hh in models EGFR-TKIs intrinsic or acquired resistance from both EGFR-mutated wild-type (WT) non-small cell lung cancer (NSCLC) lines.Activation was found EGFR-WT NSCLC line resistant EGFR-TKIs. In...
Abstract Purpose: BRAF mutations are grouped in activating RAS-independent signaling as monomers (class 1–V600E) or dimers 2–codons 597/601), and RAS-dependent with impaired kinase activity 3–codons 594/596). Although clinical, pathologic, molecular features of V600EBRAF-mutated metastatic colorectal cancer (mCRC) well known, limited data available from the two other classes. Experimental Design: Data 117 patients (92 class 1, 12 2, 13 3)-mutated mCRC were collected. A total 540 wt mCRCs...
Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid (CSF), pleural effusion (PE), and/or ascites (ASC) can be used to detect driver mutations and guide treatment decisions. We collected 42 CSF, PE, ASC samples from non‐small‐cell lung melanoma patients. Cell‐free DNA (cfDNA) was purified quantified by PNA‐Q‐PCR next‐generation sequencing. All were evaluable; clinically relevant detected...